Table 2. Analysis of factors related to TNBC PDX models.
| Factors | PDX status | |||
|---|---|---|---|---|
| Failure (%) | Success (%) | p-value | ||
| Age(years) | <60 | 29 (63.0%) | 14 (73.7%) | 0.410 |
| ≥60 | 17 (37.0%) | 5 (26.3%) | ||
| T stage | -T1 | 24 (54.5%) | 5 (26.3%) | 0.070 |
| T2 | 17 (38.6%) | 10 (52.6%) | ||
| T3-T4 | 3 (6.8%) | 4 (21.1%) | ||
| Nodal status | Negative | 28 (63.6%) | 8 (47.1%) | 0.238 |
| Positive | 16 (36.4%) | 9 (52.9%) | ||
| Histologic grade | I/II | 19 (45.2%) | 3 (15.8%) | 0.027 |
| III | 23 (54.8%) | 16 (84.2%) | ||
| Ki67 (%, n = 79) | <39 (n = 41) | 23 (52.3%) | 3 (16.7%) | 0.010 |
| ≥39 (n = 38) | 21 (47.7%) | 15 (83.3%) | ||
| BRCA mutation | Absent | 43(93.5%) | 14(73.7%) | 0.027 |
| Present | 3(6.5%) | 5(26.3%) | ||
| Survival status | Live | 44(95.7%) | 15(78.9%) | 0.034 |
| Death | 2(4.3%) | 4(21.1%) | ||
| Aggressive diseases* | Absent | 37 (80.4%) | 10 (52.6%) | 0.023 |
| Present | 9 (19.6%) | 9 (47.4%) | ||
ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor; Ki67: cell proliferation index
* Aggressive diseases were considered to be progressive diseases during neoadjuvant chemotherapy, recurrent, and metastatic disease